The four types of leukemia are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). These four types come from two simple distinctions: which blood cell line is affected (myeloid or lymphoid) and how quickly the disease progresses (acute or chronic). Understanding those two axes makes the whole classification system click into place.
How the Four Types Are Defined
Your bone marrow produces two main families of blood cells. Lymphoid cells become lymphocytes, a type of white blood cell central to your immune system. Myeloid cells produce red blood cells, platelets, and other white blood cells that aren’t lymphocytes. Leukemia starts when one of these cell lines begins growing out of control.
The second distinction is speed. Acute leukemia occurs when development halts early in a cell’s life cycle, leaving immature cells (called blasts) that multiply rapidly and crowd out healthy blood cells. Chronic leukemia results from a failure later in the cell life cycle, after cells have partially or fully matured. These cells accumulate more slowly, which is why chronic forms can go undetected for years.
Combine the two cell lines with the two speeds and you get the four types.
Acute Lymphoblastic Leukemia (ALL)
ALL is the most common cancer in children, accounting for roughly 25% of all cancer diagnoses in kids under 15. It develops when immature lymphoid cells freeze in an early stage, filling the bone marrow with blasts that can’t function as real immune cells. Symptoms tend to appear suddenly: fatigue, easy bruising, frequent infections, bone pain, and sometimes swollen lymph nodes.
The good news is that childhood ALL has become one of oncology’s biggest success stories. Five-year survival rates for children under 15 have climbed from about 60% decades ago to approximately 90% today. Adolescents aged 15 to 19 have seen a similar jump, from 36% in the late 1970s to 78% in recent years. Adults with ALL generally face tougher odds, but newer treatments, including engineered immune cell therapies (CAR-T), now have FDA-approved options for both pediatric and adult patients with B-cell ALL.
Acute Myeloid Leukemia (AML)
AML follows the same “acute” pattern as ALL, but it strikes the myeloid cell line instead. Immature myeloid cells pile up in the bone marrow, suppressing normal production of red blood cells, platelets, and functional white blood cells. That’s why people with AML often present with anemia, unusual bleeding or bruising, and infections that won’t resolve.
AML is more common in adults and tends to be more aggressive than chronic forms. The overall five-year relative survival rate sits around 33%, though outcomes vary enormously depending on a person’s age and the specific genetic features of their cancer. Smoking is a notable risk factor: researchers estimate about 20% of AML cases are linked to tobacco use. Long-term exposure to high levels of benzene, a solvent found in some industrial workplaces, and exposure to high-dose radiation are also established risk factors.
Chronic Lymphocytic Leukemia (CLL)
CLL is the slow-growing counterpart to ALL. Mature-looking but dysfunctional lymphocytes accumulate in the blood, bone marrow, and lymph nodes over months or years. Many people are diagnosed through a routine blood test before they ever feel sick.
Because CLL can progress so slowly, not everyone needs treatment right away. Doctors use staging systems to figure out who benefits from immediate therapy and who can safely be monitored. The Rai system, widely used in the United States, has five stages (0 through 4) based on rising lymphocyte counts, swollen lymph nodes, enlarged liver or spleen, low red blood cell counts, and low platelet counts. People at stage 0 may go years with no treatment at all, while stage 3 or 4 typically calls for intervention.
CLL may also be linked to Agent Orange exposure, the chemical herbicide used during the Vietnam War. For patients whose disease eventually progresses through other treatments, CAR-T cell therapy is now an FDA-approved option.
Chronic Myeloid Leukemia (CML)
CML has one of the clearest genetic signatures of any cancer. In nearly all cases, a piece of chromosome 9 swaps places with a piece of chromosome 22, creating what’s called the Philadelphia chromosome. This swap fuses two genes together, producing an abnormal protein that drives myeloid cells to multiply without the usual checks.
The most common physical finding at diagnosis is an enlarged spleen, present in more than half of patients, sometimes extending well below the rib cage. An enlarged liver can also occur. CML typically moves through three phases: a chronic phase that can last years with mild or no symptoms, an accelerated phase where the disease picks up speed, and a blast crisis that resembles acute leukemia, with bleeding, skin changes, and rapidly rising immature cell counts.
CML’s story changed dramatically with the development of targeted pills called tyrosine kinase inhibitors (TKIs). These drugs block the exact abnormal protein produced by the Philadelphia chromosome. Before TKIs, CML was often fatal within a few years. Now most people diagnosed in the chronic phase can expect near-normal life expectancy with daily oral medication. Newer TKIs have also been developed for patients whose disease becomes resistant to first-line options.
Shared Risk Factors Across Types
Some risk factors cut across multiple leukemia types. Exposure to high-dose radiation, whether from a nuclear accident, atomic weapons production, or previous radiation therapy, raises the risk for several forms. Long-term workplace exposure to benzene is another established cause. Certain genetic conditions also carry elevated risk: people with Down syndrome, Fanconi anemia, and several other inherited syndromes are more likely to develop leukemia.
That said, most people diagnosed with leukemia have no identifiable risk factor at all. The disease can develop in anyone, at any age, though the specific type strongly influences who it tends to affect: ALL peaks in early childhood, AML and CLL are more common in older adults, and CML most often appears in middle age.
How the Four Types Compare at a Glance
- ALL: Acute, lymphoid cells, most common in children, highest survival rates in pediatric patients (around 90% at five years).
- AML: Acute, myeloid cells, more common in adults, overall five-year survival around 33%, linked to smoking and benzene exposure.
- CLL: Chronic, lymphoid cells, often found incidentally in older adults, may not require immediate treatment, staged by lymph node involvement and blood counts.
- CML: Chronic, myeloid cells, defined by the Philadelphia chromosome, transformed by targeted oral therapy into a manageable long-term condition for most patients.